Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Ovid Therapeutics Inc’s stock clocked out at $0.3, down -11.95% from its previous closing price of $0.34. In other words, the price has decreased by -$11.95 from its previous closing price. On the day, 8.88 million shares were traded. OVID stock price reached its highest trading level at $0.3495 during the session, while it also had its lowest trading level at $0.302.
Ratios:
To gain a deeper understanding of OVID’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.93 and its Current Ratio is at 4.93. In the meantime, Its Debt-to-Equity ratio is 0.24 whereas as Long-Term Debt/Eq ratio is at 0.22.
On April 30, 2024, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $9.
On April 29, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $9.H.C. Wainwright initiated its Buy rating on April 29, 2024, with a $9 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 26 ’25 when ALEXANDER MARGARET A. sold 5,279 shares for $0.56 per share. The transaction valued at 2,956 led to the insider holds 73,406 shares of the business.
Rona Jeffrey A sold 3,902 shares of OVID for $2,185 on Feb 26 ’25. The CBFO now owns 67,973 shares after completing the transaction at $0.56 per share. On Jan 27 ’25, another insider, ALEXANDER MARGARET A., who serves as the President and COO of the company, bought 6,810 shares for $0.73 each. As a result, the insider paid 4,971 and bolstered with 34,935 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OVID now has a Market Capitalization of 21475070 and an Enterprise Value of -7090927. For the stock, the TTM Price-to-Sale (P/S) ratio is 39.05 while its Price-to-Book (P/B) ratio in mrq is 0.36. Its current Enterprise Value per Revenue stands at -12.94 whereas that against EBITDA is 0.134.
Stock Price History:
The Beta on a monthly basis for OVID is 0.12, which has changed by -0.649652 over the last 52 weeks, in comparison to a change of 0.12748289 over the same period for the S&P500. Over the past 52 weeks, OVID has reached a high of $1.47, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -0.58%, while the 200-Day Moving Average is calculated to be -58.03%.
Shares Statistics:
It appears that OVID traded 707.86K shares on average per day over the past three months and 2138830 shares per day over the past ten days. A total of 71.11M shares are outstanding, with a floating share count of 59.51M. Insiders hold about 16.32% of the company’s shares, while institutions hold 54.79% stake in the company. Shares short for OVID as of 1749772800 were 2498318 with a Short Ratio of 3.53, compared to 1747267200 on 1628743. Therefore, it implies a Short% of Shares Outstanding of 2498318 and a Short% of Float of 4.2.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Ovid Therapeutics Inc (OVID) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.12 and low estimates of -$0.16.
Analysts are recommending an EPS of between -$0.52 and -$0.63 for the fiscal current year, implying an average EPS of -$0.58. EPS for the following year is -$0.63, with 3.0 analysts recommending between -$0.4 and -$0.75.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for OVID’s current fiscal year. The highest revenue estimate was $570k, while the lowest revenue estimate was $100k, resulting in an average revenue estimate of $322.86k. In the same quarter a year ago, actual revenue was $566k
